10-Q: SI-BONE Reports First Quarter 2024 Results with Revenue Growth and Continued Strategic Investments

SI-BONE, Inc. announced its first quarter 2024 financial results, highlighting a 16% increase in revenue compared to the same period last year, driven primarily by growth in U.S. sales.

Summary

• SI-BONE, Inc. reported a revenue of $37.9 million for the first quarter of 2024, a 16% increase compared to $32.7 million in the first quarter of 2023.
• The company's gross profit was $29.9 million, with a gross margin of 79%, slightly lower than the 82% reported in the same period last year.
• Operating expenses totaled $41.9 million, including $29.4 million in sales and marketing, $4.3 million in research and development, and $8.2 million in general and administrative costs.
• The net loss for the quarter was $10.9 million, or $0.27 per share, compared to a net loss of $11.1 million, or $0.32 per share, in the first quarter of 2023.
• The company's cash and marketable securities totaled $157.8 million as of March 31, 2024, compared to $166.0 million at the end of 2023.
• SI-BONE continues to invest in expanding its sales force, engaging physicians, and developing new products, including the recent launch of iFuse INTRA in January 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and strategic investments, but also acknowledges ongoing losses and potential future capital needs. The sentiment is cautiously optimistic.

Positives

• Revenue increased by 16% year-over-year, indicating strong market demand for SI-BONE's products.
• The company has made significant investments in its sales force, which has grown to 85 territory sales managers and 67 clinical support specialists in the U.S.
• SI-BONE is actively expanding its reach in ambulatory surgery centers (ASCs), a growing market for minimally invasive procedures.
• The company continues to invest in research and development, with $4.3 million spent in Q1 2024, demonstrating a commitment to innovation.
• The net loss per share improved compared to the same period last year, suggesting progress towards profitability.
• The company has a strong cash position with $157.8 million in cash and marketable securities.

Negatives

• The gross margin decreased to 79% in Q1 2024, compared to 82% in Q1 2023, due to procedure and product mix.
• The company continues to operate at a net loss, with a loss of $10.9 million in Q1 2024.
• Operating expenses remain high at $41.9 million, reflecting significant investments in sales, marketing, and R&D.
• The company has an accumulated deficit of $411.3 million, indicating a history of losses.
• The company is reliant on a limited number of suppliers, which may impact the availability of instruments and materials.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to market conditions, competition, and regulatory approvals.
• The company's ability to achieve profitability depends on its ability to increase sales, manage costs, and obtain favorable reimbursement for its products.
• The company is subject to risks related to its debt obligations, including the possibility of default if it fails to comply with financial covenants.
• The company's reliance on third-party manufacturers and suppliers exposes it to supply chain disruptions and potential cost increases.
• The company's international operations are subject to risks related to foreign currency fluctuations and regulatory requirements.
• The company's business is affected by seasonal variations, with lower sales typically experienced in the summer months.

Future Outlook

The company believes its existing cash and marketable securities will enable it to fund operating expenses and capital expenditure requirements over the next 12 months. However, the company may need to raise additional capital in the future due to various factors, including potential disruptions in the healthcare operating environment and uncertainties affecting the economic and capital markets environment.

Management Comments

• Management is focused on expanding access to solutions, increasing physician penetration, launching new products, addressing human capital needs, and gaining operational efficiencies.
• The company is making targeted investments in digital marketing initiatives to drive patient awareness and connect patients with physicians.
• Management is working closely with suppliers to reduce lead time for implants and reduce the overall cost of implants as they scale.

Industry Context

SI-BONE operates in the medical device industry, specifically focusing on solutions for musculoskeletal disorders of the sacropelvic anatomy. The company's growth is influenced by trends in minimally invasive surgical procedures, the increasing adoption of ASCs, and the demand for effective treatments for sacroiliac joint dysfunction and pelvic fractures. The company competes with other medical device companies in the orthopedic and spinal implant markets.

Comparison to Industry Standards

• SI-BONE's revenue growth of 16% year-over-year is a positive indicator, suggesting strong market demand for its products. This growth rate is above the average for the medical device industry, which typically sees single-digit growth.
• The company's gross margin of 79% is within the typical range for medical device companies, but the slight decrease from 82% in the previous year indicates potential challenges in cost management or pricing strategies.
• The company's operating expenses are relatively high, reflecting its investment in sales, marketing, and R&D. This is common for growth-stage medical device companies that are focused on expanding their market presence and developing new products.
• SI-BONE's net loss is not unusual for a company in its growth phase, but the company will need to demonstrate a clear path to profitability to maintain investor confidence.
• Compared to competitors like Medtronic, Stryker, and Zimmer Biomet, SI-BONE is a smaller company with a more focused product portfolio. However, its specialization in sacropelvic solutions gives it a competitive advantage in this niche market.

Related Party Transactions

• The company had a joint development agreement with SeaSpine Orthopedics Corporation, which recently merged with Orthofix Medical, Inc. However, this is no longer a related party transaction as of October 4, 2023.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth but concerned about the ongoing losses and potential need for additional capital.
• Employees may benefit from the company's investments in talent development and a diverse and inclusive workplace.
• Customers (physicians and healthcare facilities) may benefit from the company's innovative products and training programs.
• Suppliers may benefit from the company's growing demand for implants and instruments.
• Creditors may be concerned about the company's debt obligations and financial performance.

Next Steps

• The company will continue to expand its sales force and engage physicians to drive adoption of its products.
• The company will continue to invest in research and development to bring new and differentiated solutions to the market.
• The company will continue to monitor and respond to employee sentiment to enhance employee retention and job satisfaction.
• The company will continue to evolve its business processes to identify, measure, and improve operational efficiency.
• The company anticipates results from the SILVIA study in 2025 and the SAFFRON study in late 2024.

Key Dates

Keywords

sacroiliac joint, spinal fusion, pelvic fixation, medical devices, iFuse, orthopedic, surgical implants, minimally invasive, clinical trials, reimbursement